Lorlatinib in previously-treated ALK-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study

Cancer Science
Takashi SetoMakoto Nishio

Abstract

Lorlatinib is a potent, brain-penetrant, 3rd-generation anaplastic lymphoma kinase (ALK)/ROS proto-oncogene 1 (ROS1) tyrosine kinase inhibitor (TKI) active against most known resistance mutations. This is an ongoing phase 1/2, multinational study (NCT01970865) investigating the efficacy, safety, and pharmacokinetics of lorlatinib in ALK-rearranged/ROS1-rearranged advanced non-small cell lung cancer (NSCLC) with or without intracranial (IC) metastases. Because patterns of ALK TKI use in Japan differ from other regions, we present a subgroup analysis among Japanese patients. Patients were enrolled into 6 expansion (EXP) cohorts based on ALK/ROS1 mutation status and treatment history. Primary endpoint was objective response rate (ORR) and IC-ORR by independent central review. Secondary endpoints included pharmacokinetic evaluations. At data cutoff, 39 ALK-rearranged /ROS1-rearranged Japanese patients were enrolled across the 6 expansion cohorts; all received lorlatinib 100 mg once daily. Thirty-one ALK-rearranged patients previously treated with ≥1 ALK TKI (EXP2 through EXP5) were evaluable for ORR and 15 were evaluable for IC-ORR. ORR and IC-ORR for Japanese in EXP2-5 were 54.8% (95% Confidence Interval [CI]: 36.0-72.7) and 46.7%...Continue Reading

References

Jul 6, 2005·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Outi NieminenKatrina Nordström
Jan 10, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Leila G Saldanha
Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jussi P KoivunenPasi A Jänne
Dec 17, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Benjamin SolomonD Ross Camidge
Mar 23, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel B CostaKeith D Wilner
Jun 4, 2013·The New England Journal of Medicine·Alice T ShawPasi A Jänne
Mar 29, 2014·The New England Journal of Medicine·Alice T ShawJeffrey A Engelman
Mar 29, 2014·Cancer Discovery·Luc FribouletJeffrey A Engelman
Dec 4, 2014·The New England Journal of Medicine·Benjamin J SolomonUNKNOWN PROFILE 1014 Investigators
Nov 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sai-Hong Ignatius OuDong-Wan Kim
Jun 7, 2017·The New England Journal of Medicine·Solange PetersUNKNOWN ALEX Trial Investigators
Jul 10, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·James Chih-Hsin YangAlice T Shaw
Apr 19, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S NovelloJ Wolf
Oct 4, 2018·The New England Journal of Medicine·D Ross CamidgeSanjay Popat
May 3, 2019·International Journal of Clinical Oncology·Hiroaki AkamatsuNobuyuki Yamamoto

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01970865

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.